Trius Therapeutics Commends Congressional Approval of Incentives to Develop Innovative Antibiotics – msnbc.com

SAN DIEGO, June 27, 2012 (GLOBE NEWSWIRE) — Trius Therapeutics, Inc. (Nasdaq:TSRX) today commented on the approval by the United States Congress of the Prescription Drug Users Fee Act ( PDUFA V ) which contains key incentives for antibiotic …